- Ağrı Tıp Fakültesi Dergisi
- Volume:2 Issue:3
- Comparison of Non-invasive Biochemical Fibrosis Markers According to Obesity-Based Metabolic Profile...
Comparison of Non-invasive Biochemical Fibrosis Markers According to Obesity-Based Metabolic Profile in Chronic Liver Disease with Chronic Hepatitis B Etiology
Authors : Sedat Çiftel
Pages : 113-116
Doi:10.61845/agrimedical.1562045
View : 66 | Download : 76
Publication Date : 2024-10-30
Article Type : Research Paper
Abstract :Aim: The aim of this study is to investigate the impact of obesity on fibrosis by comparing fibrosis markers between obese and non-obese patients with Chronic Hepatitis B (CHB). Material and Method: A total of 172 CHB (50.6±9.4 mean aged) patients were included in this retrospective study. The patients were divided into two groups: Obese (n=72) and Non-obese (n=100). Inclusion criteria were those diagnosed with chronic hepatitis B and ≤ 50 IU/mL or undetectable HBV-DNA, and exclusion criteria were other chronic diseases other than CHB and pregnancy. The height, body weight, and waist circumferences were measured. BMI ≥30 kg/m2 was classified as the obese group. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl transferase, albumin, bilirubin, and prothrombin time were analyzed. Fibrosis-4 score (FIB-4) was calculated with the formula Age x AST / platelet count x √(ALT), and AST-Platelet Ratio Index (APRI) was calculated with the formula [AST/AST (upper limit of normal)]/ platelet count. Results: AST levels were significantly higher in obese patients (p<0.001). FIB-4 (p=0.002) and APRI (p=0.007) scores were higher in the obese group. The length of the right lobe of the liver was also significantly enlarged in the obese group (p=0.035). Conclusion: Obesity is associated withz increased fibrosis progression in CHB patients. These findings suggest that obesity may exacerbate liver damage in CHB patients and highlight the importance of managing obesity in this population to slow fibrosis progression. Further research is warranted to manage therapeutic strategies to mitigate the impact of obesity on fibrosis in CHB.Keywords : Kronik Hepatit B, Obezite, APRI, FIB-4
ORIGINAL ARTICLE URL
